What causes Alzheimer’s disease?

Alzheimer’s develops through a combination of biological changes in the brain, not a single cause:

• Protein accumulation — buildup of beta-amyloid plaques and tau tangles disrupts communication between neurons and is central to disease progression.
• Genetic factors — genes such as APOE-ε4 increase susceptibility; a small number of early-onset cases are linked to specific inherited gene mutations (APP, PSEN1, PSEN2).
• Neuronal degeneration — progressive loss of nerve cells and synaptic connections in memory-related brain regions (notably the hippocampus).
• Chronic neuroinflammation — sustained inflammatory activity in brain tissue accelerates neuronal injury and impairs the brain’s ability to clear toxic protein buildup.
• Vascular contribution — reduced cerebral blood flow and microvascular damage can compound cognitive decline, especially when cardiovascular risk factors are present.
• Metabolic and lifestyle factors — aging, oxidative stress, poorly controlled diabetes, and low physical activity are associated with higher risk and faster progression.

Why this matters for treatment planning

Because tau/amyloid burden, vascular contribution, and inflammation each play different roles, the stage and dominant driver of a patient’s decline shapes what a regenerative approach can realistically target. A patient with significant vascular contribution, for example, may need cardiovascular risk management addressed in parallel — not instead of — any stem cell protocol.

Related reading: Mechanism of Action below explains exactly how MSCs are thought to interact with these processes.

What are the symptoms of Alzheimer’s disease?

Symptoms develop gradually and worsen over time, typically beginning with subtle memory lapses before progressing to broader cognitive and functional decline:

• Memory loss that disrupts daily life — forgetting recent conversations, appointments, or repeatedly asking the same questions.
• Difficulty planning or problem-solving — trouble following a familiar recipe, managing finances, or keeping track of routine tasks.
• Disorientation to time or place — losing track of dates, seasons, or getting lost in familiar surroundings.
• Language and word-finding difficulty — struggling mid-conversation to find the right word or losing the thread of a discussion.
• Mood and personality changes — increased irritability, withdrawal from social activities, anxiety, or suspicion.

When to seek evaluation

None of these signs alone confirm Alzheimer’s — they can also indicate other reversible conditions (thyroid dysfunction, vitamin B12 deficiency, medication interactions, depression) that mimic dementia symptoms and are treated very differently. If you or a family member notice these changes, the next step is a full neurological and cognitive evaluation — see Diagnosis — not a stem cell consultation directly.

How is Alzheimer’s disease diagnosed?

At Viezec, no regenerative protocol is proposed without a completed neurological work-up confirming diagnosis and stage:

If you already have recent imaging and cognitive test results (within the last 6–12 months), you can upload them for a free case review rather than repeating the full work-up.

Note on staging: Candidacy for stem cell therapy at Viezec depends heavily on disease stage — see Who Is a Candidate below — since research to date concentrates on early-to-moderate stages, where meaningful numbers of neurons and synaptic connections remain intact.

Stem Cell Treatment for Alzheimer’s Disease

How does it work?

Stem cell therapy for Alzheimer’s uses mesenchymal stem cells, most often sourced from bone marrow, adipose tissue, or umbilical cord tissue, to address neuronal loss, chronic neuroinflammation, and impaired neuroregeneration rather than protein buildup directly. MSCs are studied for releasing neurotrophic growth factors, reducing neuroinflammatory signaling, and supporting the survival of existing neural connections — see full mechanism detail under Mechanism.

Who is a candidate?

You may be considered a candidate if you have:

• A confirmed diagnosis of early-to-moderate stage Alzheimer’s disease (via the tests listed under Diagnosis)
• Sufficient remaining cognitive and neurological function for meaningful stabilization to be a realistic goal
• No contraindicating conditions identified during medical evaluation (active cancer, uncontrolled infection, certain cardiovascular conditions)

You are not likely to be a suitable candidate if the diagnosis is late-stage/severe Alzheimer’s with extensive neuronal loss, or if cognitive decline is caused by a reversible condition (thyroid dysfunction, B12 deficiency) that hasn’t yet been ruled out or treated — these should be addressed first, often resolving the issue without any regenerative intervention.

What to expect: the treatment process at Viezec

1. Neurological evaluation and imaging review — MRI/CT, cognitive scoring, and staging.
2. Cell sourcing — autologous (patient’s own bone marrow/adipose) or allogeneic (screened donor, most often umbilical cord) selection based on medical assessment.
3. Cell isolation and expansion — under GMP-certified laboratory conditions.
4. Administration — via intravenous or targeted delivery route depending on the delivery method selected for your case.
5. Supportive care and follow-up — cognitive therapy, nutritional guidance, and structured reassessment over the following months.

Most international patients require a 7–10 day in-country stay for evaluation, treatment, and initial monitoring, with follow-up continuing remotely for 6–12 months. See visa assistance and plan-your-visit resources for travel logistics.

Delivery Methods for Alzheimer’s Stem Cell Therapy

The route of administration affects how directly stem cells reach affected brain tissue, and Viezec’s specialists select the appropriate method based on your neurological evaluation and disease stage:

• Intravenous (IV) infusion — the most common route; cells circulate systemically and are studied for their ability to modulate inflammation and support neuroprotection broadly, with a subset able to cross into central nervous system tissue.
• Intrathecal delivery (into the cerebrospinal fluid via lumbar puncture) — positions cells closer to the central nervous system and is used in select protocols based on specialist assessment.
• Combined/staged protocols — some treatment plans use more than one delivery method across sessions, guided by follow-up response.

All cell preparation takes place in GMP-certified, ISO-standardized laboratories, using ethically sourced cells — Viezec does not use embryo-derived or fetal cell sources. For a general explanation of how delivery method selection works across conditions, see Stem Cell Delivery Methods.

Safety and quality commitments

• GMP, ISO, and NABL-certified laboratory environments
• Ethically sourced cells only — no embryonic or fetal tissue
• Sterility and infection-control protocols at every processing stage
• Continuous neurological monitoring before, during, and after administration

Improvements & Results

Improvement after stem cell therapy for Alzheimer’s is tracked through structured cognitive and behavioral assessment, not self-reported impressions alone.

Memory and attention

Some patients report improved recall of recent events and longer attention span during conversations and tasks — assessed via repeat cognitive testing (MMSE/MoCA) rather than informal observation alone.

Daily functioning

Structured follow-up sometimes shows improved ability to manage routine activities (dressing, meal preparation) with reduced caregiver assistance — tracked via functional independence scales.

Rate of cognitive decline

The most consistently studied outcome is a slower rate of decline compared to expected natural progression, rather than outright improvement — this distinction matters and should be communicated clearly to patients and families.

Mechanism of Action: How Stem Cells May Support Brain Health in Alzheimer’s Disease

MSC-based therapy is studied as a biological modulator, not a neuron-replacement approach:

• Neuroprotection — MSCs secrete factors thought to help protect surviving neurons from further degeneration and toxic protein exposure.
• Neuroinflammation regulation — modulating chronic inflammatory activity, a major driver of progressive cognitive impairment.
• Neurotrophic support — release of growth factors (e.g., BDNF-related signaling) associated with healthier synaptic connections.
• Oxidative stress reduction — antioxidant-related effects that may reduce ongoing cellular damage in brain tissue.

This is consistent with how MSCs are studied across other neurological conditions Viezec treats — see Parkinson’s Disease and Stroke for comparable mechanism discussions, or the general Stem Cell Healing Potential page for the underlying science.

At Viezec, our commitment for Alzheimer’s care is transparency over overstated claims:

• No cure claims. Stem cell therapy is presented as a researched, supportive option — never marketed as a cure.
• Diagnosis and staging before treatment. No protocol is proposed without completed neurological evaluation confirming disease stage.
• Named, credentialed medical oversight. (Add the treating neurologist’s name and credentials here directly, as recommended on your infertility page — this is your single highest-trust addition across all disease pages.)
• Accredited facilities. GMP, ISO, and NABL-certified laboratories — (insert actual registration numbers, verifiable via the relevant public registries).
• Regulatory transparency. Consistent with the disclaimer already on this page, we operate within India’s investigational-use framework for stem cell interventions and disclose this directly.
• Written cost estimates provided after evaluation, not before.
• Honest evidence communication. Where trial evidence is limited — as with Alzheimer’s — we say so directly and link the specific studies our approach draws on (see Scientific References).

Learn More About Alzheimer’s Disease Treatment

Testimonials

Hiroshi T. – Tokyo, Japan – February 2020 – ⭐⭐⭐⭐☆
“My father struggled with memory loss. After Viezec’s stem cell therapy, he became more attentive and could recall family names again.”

Elena K. – Moscow, Russia – August 2020 – ⭐⭐⭐⭐⭐
“Alzheimer’s made conversations hard. Post-treatment at Viezec, my mother’s speech improved, and she engages more actively with us.”

Samuel O. – Nairobi, Kenya – January 2021 – ⭐⭐⭐⭐☆
“Forgetfulness made life tough for my wife. Stem cell therapy at Viezec helped stabilize her memory, and she feels more connected to family life.”

Isabella M. – Buenos Aires, Argentina – September 2021 – ⭐⭐⭐⭐⭐
“My father showed clearer thinking and better mood after treatment. Viezec gave us hope that we never imagined possible.”

Lars H. – Stockholm, Sweden – March 2022 – ⭐⭐⭐⭐☆
“Alzheimer’s had made daily tasks impossible. After Viezec’s therapy, my concentration improved, and I feel more independent again.”

Amina F. – Casablanca, Morocco – October 2022 – ⭐⭐⭐⭐⭐
“My mother’s anxiety reduced after treatment. Stem cell therapy at Viezec helped her remember routines and feel calmer each day.”

George C. – Athens, Greece – April 2023 – ⭐⭐⭐⭐☆
“I had trouble recognizing familiar places. After Viezec’s therapy, my orientation improved, and I feel safer moving around.”

Fatima R. – Istanbul, Turkey – November 2023 – ⭐⭐⭐⭐⭐
“Alzheimer’s had taken away my father’s smile. Post-treatment at Viezec, his memory improved, and his personality started coming back.”

Pedro D. – Lisbon, Portugal – February 2024 – ⭐⭐⭐⭐☆
“My mother often repeated questions. After stem cell therapy at Viezec, her memory stabilized, and she engages better in conversations.”

Anna B. – Warsaw, Poland – June 2025 – ⭐⭐⭐⭐⭐
“Alzheimer’s was progressing quickly, but Viezec’s therapy slowed it down. My father remembers faces again, and family life feels brighter.”

Treatment Disclaimer

Is stem cell therapy a guaranteed treatment for Alzheimer’s?

No. Stem cell therapy for Alzheimer’s is not a guaranteed treatment, and no clinic can promise specific cognitive outcomes. It is offered as an investigational, supportive option for confirmed early-to-moderate stage cases, following full neurological evaluation, and is intended to complement — not replace — standard dementia care.

(…remainder of your existing disclaimer content carries forward as published; it already covers what-this-page-does / does-not-do, and directs to emergency care for rapid worsening — good structure, no changes needed.)

Request Medical Evaluation